CiMaas BV, a company developing cellular immunotherapy for cancer, and PharmaCell BV, a contract manufacturing organization for cellular therapies and regenerative medicine in Europe, have agreed to collaborate on the clinical development of CiMaas’ products.   PharmaCell will provide consulting services on writing GMP-compliant documents for the purpose of translating the CiMaas cell therapy processes into GMP. Options have been taken on a full technology transfer to be executed at a later da...